Bradley Thompson Quoted on Trend Among Drug and Device Makers To Outsource ResearchMedical Devices Law & Industry Report April 21, 2009
Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences Practice in the Washington, DC office, was quoted in an article about a dramatic rise in outsourcing by drug and medical device manufacturers of their research and development work to contract research organizations (CROs).
In the article, "Clinical Trials: Fast-Growing Contract Research," Thompson was quoted as saying that this investment, combined with the FDA's increasing focus on clinical trials, makes it critical for drug and device makers to carefully manage their relationships with CROs to reduce the risks inherent in such interactions. Managing these risks is optimally done through all stages of a sponsor's relationship with a CRO, such as CRO selection, contracting, and even after the project concludes, and it should involve the consideration of numerous factors
Thompson made the remarks during a BNA audioconference on April 14.